Xpert^® GBS LB XC

The Need

The Need

In the U.S., Group B Streptococcus (GBS) remains a leading cause of early onset neonatal sepsis. Rates of maternal colonization have not changed, but universal antenatal screening at 35–37 weeks along with the use of intrapartum antibiotic prophylaxis (IAP) has resulted in a decrease of early onset disease.^1,2

• Centers for Disease Control and American College of Obstetricians and Gynecologists practice guidelines recommend universal antepartum screening along with intrapartum where indicated based on risk
• Risk based IAP exposes 65–85% of GBS-negative women with risk factors to antibiotics. This has been linked to emergence of resistant strains³
• Up to 50% false negatives when testing with agar alone⁴

The Solution

The Solution

Cepheid’s GeneXpert^® system, with both Xpert^® GBS LB XC and Xpert GBS is the only solution able to fully meet CDC criteria for both antenatal and intrapartum testing, with positive results in approximately 40 minutes.

On-demand molecular testing — an ideal solution:

• System designed with Early Assay Termination (EAT) with positive samples reported STAT

- As soon as positive sample is confirmed, software concludes test and reports immediately

• Moderately complex testing with minimal hands-on time

- STAT intrapartum specimens can be performed by lab, or by labor and delivery staff

- Reduces lab’s work for antenatal screening

- Random access ensures any test on the menu can be run anytime, without the need to batch run